Target RWE, a leader in real-world evidence (RWE), has announced a significant achievement: their eosinophilic gastrointestinal disorders (EGIDs) disease state registry has enrolled over 1,000 patients. EGIDs are chronic, immune-mediated gastrointestinal diseases that can affect various parts of the digestive system and may be associated with food allergen exposure. The disorders include eosinophilic esophagitis (EoE) and eosinophilic gastroenteritis (EGE), depending on the disease’s location.
Key points from the article:
- Response to Market Need: The registry was initiated in response to market interest and the high unmet need in the EGIDs community.
- Awareness and Diagnosis: Awareness of EGIDs has grown significantly over the past decade. However, many patients still experience long durations before receiving the correct diagnosis due to the limited studies on EGIDs. The progressive nature of most EGIDs cases underscores the need for effective, long-term treatments.
- Current Treatments: Existing treatments for EGIDs offer variable response rates and often don’t provide long-term control. New therapies targeting key inflammatory mediators involved in the disease are in various development stages.
- Data Collection: The data is being curated to further understand the disease’s natural history, the EGID patient journey, and the impact of comorbidities.
- Real-World Patient Data: Target RWE aggregates diverse real-world patient data, including medical records, patient-reported outcome measures, and clinically linked biospecimens. This data aids a wide range of stakeholders, from providers to regulators and industry partners.
Target RWE is a leading real-world evidence solution that unifies real-world data sets and advanced RWE analytics in a collaborative community. The company sources unique, connected data sets across multiple therapeutic areas.